Presentation TCT 2014 Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger September 15, 2014
Presentation TCT 2014 Rivaroxaban in ACS and Atrial Fibrillation: Randomized Trials, Real-World Data, and Pioneering Efforts Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson September 15, 2014
Presentation TCT 2014 Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri September 15, 2014
Presentation TCT 2014 Comparative Analysis of Warfarin and the NOACs: Differentiating Properties, Risks, and Benefits Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Jonathan L. Halperin September 15, 2014
Presentation TCT 2014 The REG1 Anticoagulation System: Factor IX Inhibitor Using RNA Aptamer Technology Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, A. Michael Lincoff September 15, 2014
Presentation TCT 2014 Old and New Anticoagulants for Stroke Prevention: Benefits and Risks Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin September 15, 2014
Presentation TCT 2014 Putting it All Together: Anticoagulants, Rhythm Control, and LAA Closure Which Therapy for Which Patient? Presenter: Matthew J. Price, Shephal Doshi September 15, 2014
Presentation TCT 2014 ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff September 15, 2014
News Industry News New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation September 15, 2014
News Industry News Extended Follow-Up of Multicenter Trial Demonstrates Continued Superiority of Bivalirudin to Heparin with and without Glycoprotein IIB, IIIA Inhibition in Patients with Acute Myocardial Infarction September 15, 2014
Presentation TCT 2014 Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini September 14, 2014
Presentation TCT 2014 Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes Presenter: Kishore J. Harjai, Michael S. Lee September 14, 2014
News Conference News TCT 2014 LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF September 14, 2014
News Conference News TCT 2014 EUROMAX Substudy: Bivalirudin Noninferior to Heparin Plus GPI for Myocardial Reperfusion September 14, 2014
Presentation TCT 2014 Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients Presenter: Roxana Mehran, Mohamed Sobhy September 13, 2014
News Conference News TCT 2014 Meta-analysis: Less Bleeding, More Stent Thrombosis with Bivalirudin vs. Heparin After PCI September 13, 2014
News Conference News ESC 2014 ACCOAST Substudy: Prasugrel Pretreatment Linked With Increased Bleeding in NSTEMI Patients Yael L. Maxwell September 03, 2014
News Industry News Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes September 02, 2014
News Daily News HORIZONS-AMI Substudy: Anticoagulation After Primary PCI Yields Worse Outcomes September 02, 2014
News Daily News With Some Caveats, SAFE-PCI Shows Positive Signs for Radial Access in Women Yael L. Maxwell September 02, 2014